Skip to content
DataLookout
Menu

TREAT-IIHNCT07946315

Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Mean daily acetazolamide dose at 12 months
Timeframe: 12 months

Secondary (38)

Cumulative acetazolamide dose
Between-group comparison of acetazolamide dose at each study visit
Time to initiation of acetazolamide down-titration (days)
Remission rate (off acetazolamide)
Best-corrected visual acuity
Show 33 moreShow less
Visual field perimetric mean deviation
Papilledema Frisén grade
Peripapillary retinal nerve fiber layer (pRNFL) thickness
Combined ganglion cell-inner plexiform layer (GCIPL) thickness
Peripapillary capillary density on optical coherence tomography angiography (OCT-A)
Change in lumbar puncture opening pressure
Proportion of patients with new spontaneous cerebrospinal fluid leak
Composite National Eye Institute Visual Function Questionnaire 25 (VFQ-25) plus 10-item neuro-ophthalmology supplement score
Migraine disability assessment test (MIDAS)
Headache impact test (HIT-6)
14-day headache score
Time to symptom control
Proportion with symptom control
Brain fog scale score
Percent reduction in body weight
Body Mass Index (BMI)
Abdominal circumference
Body fat mass
Percent body fat
Android/gynoid ratio
Bone mineral density
Structural magnetic resonance imaging (MRI) features of intracranial hypertension
Pituitary gland height
Optic nerve sheath diameter (mean)
Combined conduit score (CCS)
Diffusion tensor imaging along the perivascular space (DTI-ALPS) index
Epworth Sleepiness Scale (ESS)
STOP-Bang score (S-Snoring; T-Tired; O-Observed; P-Pressure; B-BMI; A-Age; N-Neck; G-Gender)
Apnea-hypopnea index (AHI)
Adverse Events
Serious Adverse Events
Treatment-related withdrawals
Treatment failures

Arms and interventions

Acetazolamide + TirzepatideExperimental

Extended-release acetazolamide titrated per protocol (up to 4 g/day) plus weekly subcutaneous tirzepatide starting 2.5 mg and escalated monthly as tolerated to a maximum of 15 mg weekly, for 12 months; standard nutrition and exercise counseling.

Acetazolamide + PlaceboPlacebo comparator

Extended-release acetazolamide titrated per protocol (up to 4 g/day) plus weekly subcutaneous placebo injection on the same escalation schedule, for 12 months; standard nutrition and exercise counseling.

Drugs: Tirzepatide, Placebo, Acetazolamide

Sites

1 site in 1 country

  • Brigham and Women's HospitalBoston, Massachusetts, United States